GILEAD SCIENCES, INC. — Insider Transactions
Form 4 filings by directors, officers, and 10%+ shareholders
SEC rules require corporate insiders — including directors, executive officers, and any shareholder owning more than 10% of a company's shares — to report changes in their ownership within two business days of a transaction. These disclosures are filed as Form 4. Open-market purchases (code P) are generally considered the most meaningful signal, as insiders are spending their own money.
| Insider | Title | Type | Shares | Price | Value | Owns After | Date |
|---|---|---|---|---|---|---|---|
| LEE WILLIAM A | SVP, Research | Sale | 300 | $69.50 | $20,850 | 68,099 | Oct 23, 2006 |
| MOORE GORDON EARLE | — | Option Exercise | 56,000 | $3.13 | $175,280 | 458,648 | Oct 19, 2006 |
| Alton Gregg H | SVP, General Counsel | Sale | 1,200 | $67.00 | $80,400 | 24,395 | Oct 12, 2006 |
| MARTIN JOHN C | President and CEO | Sale | 5,000 | $64.53 | $322,650 | 755,729 | Oct 10, 2006 |
| Alton Gregg H | SVP, General Counsel | Sale | 300 | $65.25 | $19,575 | 27,645 | Oct 2, 2006 |
| Alton Gregg H | SVP, General Counsel | Sale | 1,112 | $67.00 | $74,504 | 25,683 | Sep 27, 2006 |
| BERG PAUL | — | Sale | 1,010 | $63.25 | $63,883 | 14,490 | Sep 13, 2006 |
| MARTIN JOHN C | President and CEO | Sale | 7,500 | $62.75 | $470,625 | 756,909 | Sep 12, 2006 |
| Montgomery Alan Bruce | SVP, Respiratory Therapeutics | Award / Grant | 14,000 | — | — | 14,280 | Sep 11, 2006 |
| Alton Gregg H | SVP, General Counsel | Sale | 100 | $63.84 | $6,384 | 25,136 | Sep 1, 2006 |
| Alton Gregg H | SVP, General Counsel | Sale | 1,000 | $64.10 | $64,100 | 29,486 | Aug 17, 2006 |
| TOOLE JOHN J | SVP, Clinical Research | Sale | 298 | $63.94 | $19,054 | 13,751 | Aug 16, 2006 |
| TOOLE JOHN J | SVP, Clinical Research | Sale | 100 | $63.72 | $6,372 | 13,551 | Aug 16, 2006 |
| DENNY JAMES M | — | Sale | 1,083 | $62.08 | $67,233 | 78,417 | Aug 9, 2006 |
| LEE WILLIAM A | SVP, Research | Sale | 1,334 | $62.72 | $83,668 | 37,847 | Aug 9, 2006 |
| YOUNG KEVIN | EVP, Commercial Operations | Sale | 3,162 | $62.02 | $196,107 | 9,324 | Aug 9, 2006 |
| DENNY JAMES M | — | Sale | 400 | $62.18 | $24,872 | 75,000 | Aug 9, 2006 |
| LEE WILLIAM A | SVP, Research | Sale | 29,465 | $61.90 | $1,823,884 | 37,679 | Aug 8, 2006 |
| BISCHOFBERGER NORBERT W | EVP, Research | Sale | 12,500 | $60.50 | $756,250 | 571,081 | Aug 1, 2006 |
| MARTIN JOHN C | President and CEO | Sale | 6,000 | $60.53 | $363,180 | 783,769 | Aug 1, 2006 |
| Alton Gregg H | SVP, General Counsel | Sale | 5,000 | $62.00 | $310,000 | 32,036 | Jul 25, 2006 |
| MILLIGAN JOHN F | EVP, Chief Financial Officer | Sale | 500 | $60.94 | $30,470 | 98,521 | Jul 25, 2006 |
| BERG PAUL | — | Sale | 100 | $61.51 | $6,151 | 13,100 | Jul 12, 2006 |
| BERG PAUL | — | Sale | 200 | $61.75 | $12,350 | 10,500 | Jul 12, 2006 |
| Alton Gregg H | SVP, General Counsel | Option Exercise | 1,000 | $9.81 | $9,810 | 35,248 | Jun 23, 2006 |
| MARTIN JOHN C | President and CEO | Option Exercise | 19,968 | $2.86 | $57,108 | 736,909 | May 18, 2006 |
| BISCHOFBERGER NORBERT W | EVP, Research | Sale | 7,500 | $55.65 | $417,375 | 578,581 | May 17, 2006 |
| DENNY JAMES M | — | Sale | 2,000 | $57.67 | $115,340 | 63,000 | May 10, 2006 |
| BERG PAUL | — | Option Exercise | 6,500 | $4.78 | $31,070 | 15,500 | May 10, 2006 |
| DAVIGNON ETIENNE | — | Award / Grant | 7,250 | — | — | 219,250 | May 9, 2006 |
| LEE WILLIAM A | SVP, Research | Option Exercise | 20,000 | $3.27 | $65,400 | 37,679 | May 4, 2006 |
| LEE WILLIAM A | SVP, Research | Option Exercise | 10,000 | $3.27 | $32,700 | 17,679 | Apr 28, 2006 |
| BERG PAUL | — | Sale | 600 | $59.24 | $35,544 | 12,700 | Mar 8, 2006 |
| Alton Gregg H | SVP, General Counsel | Option Exercise | 2,994 | $7.41 | $22,186 | 22,348 | Mar 6, 2006 |
| DENNY JAMES M | — | Sale | 100 | $59.65 | $5,965 | 65,000 | Mar 6, 2006 |
| MARTIN JOHN C | President and CEO | Sale | 22,000 | $57.02 | $1,254,440 | 779,941 | Feb 27, 2006 |
| YANG TAIYIN | SVP, Pharm Dev & Mfg | Sale | 200 | $61.20 | $12,240 | 223,151 | Feb 22, 2006 |
| MARTIN JOHN C | President and CEO | Sale | 7,000 | $61.76 | $432,320 | 738,217 | Feb 16, 2006 |
| LEE WILLIAM A | SVP, Research | Sale | 19,900 | $60.75 | $1,208,925 | 362 | Feb 14, 2006 |
| BISCHOFBERGER NORBERT W | EVP, Research | Sale | 1,000 | $59.23 | $59,230 | 523,581 | Feb 14, 2006 |
| YANG TAIYIN | SVP, Pharm Dev & Mfg | Option Exercise | 3,000 | $9.34 | $28,020 | 207,079 | Feb 13, 2006 |
| TOOLE JOHN J | SVP, Clinical Research | Sale | 34,872 | $59.34 | $2,069,304 | 14,151 | Feb 9, 2006 |
| LEE WILLIAM A | SVP, Research | Sale | 10,000 | $60.22 | $602,200 | 7,679 | Feb 8, 2006 |
| MILLIGAN JOHN F | EVP, Chief Financial Officer | Sale | 3,900 | $60.56 | $236,184 | 101,421 | Feb 6, 2006 |
| YOUNG KEVIN | EVP, Commercial Operations | Sale | 200 | $61.19 | $12,238 | 11,754 | Feb 3, 2006 |
| Alton Gregg H | SVP, General Counsel | Award / Grant | 10,000 | $13.60 | $136,000 | 29,354 | Feb 2, 2006 |
| YOUNG KEVIN | EVP, Commercial Operations | Sale | 17,890 | $60.35 | $1,079,662 | 1,254 | Feb 2, 2006 |
| DAVIGNON ETIENNE | — | Award / Grant | 1,000 | — | — | 212,000 | Jan 26, 2006 |